Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 4
2004 5
2005 2
2006 8
2007 5
2008 3
2009 2
2010 7
2011 4
2012 6
2013 4
2014 10
2015 5
2016 8
2017 6
2018 5
2019 4
2020 3
2021 2
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D; Huntington Study Group KINECT-HD Collaborators. Furr Stimming E, et al. Lancet Neurol. 2023 Jun;22(6):494-504. doi: 10.1016/S1474-4422(23)00127-8. Lancet Neurol. 2023. PMID: 37210099 Clinical Trial.
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M; Huntington Study Group SIGNAL investigators. Feigin A, et al. Nat Med. 2024 Feb;30(2):606. doi: 10.1038/s41591-022-02070-0. Nat Med. 2024. PMID: 36195687 Free PMC article. No abstract available.
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M; Huntington Study Group SIGNAL investigators. Feigin A, et al. Nat Med. 2022 Oct;28(10):2183-2193. doi: 10.1038/s41591-022-01919-8. Epub 2022 Aug 8. Nat Med. 2022. PMID: 35941373 Free PMC article. Clinical Trial.
Altered cortical processing of sensory input in Huntington disease mouse models.
Sepers MD, Mackay JP, Koch E, Xiao D, Mohajerani MH, Chan AW, Smith-Dijak AI, Ramandi D, Murphy TH, Raymond LA. Sepers MD, et al. Among authors: raymond la. Neurobiol Dis. 2022 Jul;169:105740. doi: 10.1016/j.nbd.2022.105740. Epub 2022 Apr 20. Neurobiol Dis. 2022. PMID: 35460870 Free article.
Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease.
Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, Caron NS, Østergaard ME, Anderson LM, Xie Y, Cengio LD, Findlay-Black H, Doty CN, Fitsimmons B, Swayze EE, Seth PP, Raymond LA, Frank Bennett C, Hayden MR. Southwell AL, et al. Among authors: raymond la. Sci Transl Med. 2018 Oct 3;10(461):eaar3959. doi: 10.1126/scitranslmed.aar3959. Sci Transl Med. 2018. PMID: 30282695
Characteristics and outcomes of Canadian MD/PhD program graduates: a cross-sectional survey.
Skinnider MA, Squair JW, Twa DDW, Ji JX, Kuzyk A, Wang X, Steadman PE, Zaslavsky K, Dey AK, Eisenberg MJ, Gagné ÈR, HayGlass KT, Lewis JF, Margetts PJ, Underhill DA, Rosenblum ND, Raymond LA. Skinnider MA, et al. Among authors: raymond la. CMAJ Open. 2017 Apr 25;5(2):E308-E314. doi: 10.9778/cmajo.20160152. CMAJ Open. 2017. PMID: 28442493 Free PMC article.
Inhibition of the mitochondrial pyruvate carrier protects from excitotoxic neuronal death.
Divakaruni AS, Wallace M, Buren C, Martyniuk K, Andreyev AY, Li E, Fields JA, Cordes T, Reynolds IJ, Bloodgood BL, Raymond LA, Metallo CM, Murphy AN. Divakaruni AS, et al. Among authors: raymond la. J Cell Biol. 2017 Apr 3;216(4):1091-1105. doi: 10.1083/jcb.201612067. Epub 2017 Mar 2. J Cell Biol. 2017. PMID: 28254829 Free PMC article.
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.
McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M; Huntington Study Group 2CARE Investigators and Coordinators. McGarry A, et al. Among authors: raymond la. Neurology. 2017 Jan 10;88(2):152-159. doi: 10.1212/WNL.0000000000003478. Epub 2016 Dec 2. Neurology. 2017. PMID: 27913695 Free PMC article. Clinical Trial.
An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes.
Southwell AL, Smith-Dijak A, Kay C, Sepers M, Villanueva EB, Parsons MP, Xie Y, Anderson L, Felczak B, Waltl S, Ko S, Cheung D, Dal Cengio L, Slama R, Petoukhov E, Raymond LA, Hayden MR. Southwell AL, et al. Among authors: raymond la. Hum Mol Genet. 2016 Sep 1;25(17):3654-3675. doi: 10.1093/hmg/ddw212. Epub 2016 Jul 4. Hum Mol Genet. 2016. PMID: 27378694 Free PMC article.
Motor onset and diagnosis in Huntington disease using the diagnostic confidence level.
Liu D, Long JD, Zhang Y, Raymond LA, Marder K, Rosser A, McCusker EA, Mills JA, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Liu D, et al. Among authors: raymond la. J Neurol. 2015 Dec;262(12):2691-8. doi: 10.1007/s00415-015-7900-7. Epub 2015 Sep 26. J Neurol. 2015. PMID: 26410751 Free PMC article.
Treatment of Huntington Disease and Comorbid Trichotillomania With Aripiprazole.
Howard AK, Krishnamoorthy A, Leavitt BR, Raymond LA, Weissman CR. Howard AK, et al. Among authors: raymond la. J Neuropsychiatry Clin Neurosci. 2015 Summer;27(3):e211-2. doi: 10.1176/appi.neuropsych.14090232. J Neuropsychiatry Clin Neurosci. 2015. PMID: 26222972 No abstract available.
LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory.
Beccano-Kelly DA, Volta M, Munsie LN, Paschall SA, Tatarnikov I, Co K, Chou P, Cao LP, Bergeron S, Mitchell E, Han H, Melrose HL, Tapia L, Raymond LA, Farrer MJ, Milnerwood AJ. Beccano-Kelly DA, et al. Among authors: raymond la. Hum Mol Genet. 2015 Mar 1;24(5):1336-49. doi: 10.1093/hmg/ddu543. Epub 2014 Oct 24. Hum Mol Genet. 2015. PMID: 25343991
Memory and synaptic deficits in Hip14/DHHC17 knockout mice.
Milnerwood AJ, Parsons MP, Young FB, Singaraja RR, Franciosi S, Volta M, Bergeron S, Hayden MR, Raymond LA. Milnerwood AJ, et al. Among authors: raymond la. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20296-301. doi: 10.1073/pnas.1222384110. Epub 2013 Nov 25. Proc Natl Acad Sci U S A. 2013. PMID: 24277827 Free PMC article.
Refining the diagnosis of Huntington disease: the PREDICT-HD study.
Biglan KM, Zhang Y, Long JD, Geschwind M, Kang GA, Killoran A, Lu W, McCusker E, Mills JA, Raymond LA, Testa C, Wojcieszek J, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group. Biglan KM, et al. Among authors: raymond la. Front Aging Neurosci. 2013 Apr 2;5:12. doi: 10.3389/fnagi.2013.00012. eCollection 2013. Front Aging Neurosci. 2013. PMID: 23565093 Free PMC article.
Synaptic dysfunction in progranulin-deficient mice.
Petkau TL, Neal SJ, Milnerwood A, Mew A, Hill AM, Orban P, Gregg J, Lu G, Feldman HH, Mackenzie IR, Raymond LA, Leavitt BR. Petkau TL, et al. Among authors: raymond la. Neurobiol Dis. 2012 Feb;45(2):711-22. doi: 10.1016/j.nbd.2011.10.016. Epub 2011 Oct 25. Neurobiol Dis. 2012. PMID: 22062772
Altered palmitoylation and neuropathological deficits in mice lacking HIP14.
Singaraja RR, Huang K, Sanders SS, Milnerwood AJ, Hines R, Lerch JP, Franciosi S, Drisdel RC, Vaid K, Young FB, Doty C, Wan J, Bissada N, Henkelman RM, Green WN, Davis NG, Raymond LA, Hayden MR. Singaraja RR, et al. Among authors: raymond la. Hum Mol Genet. 2011 Oct 15;20(20):3899-909. doi: 10.1093/hmg/ddr308. Epub 2011 Jul 20. Hum Mol Genet. 2011. PMID: 21775500 Free PMC article.
Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.
McConoughey SJ, Basso M, Niatsetskaya ZV, Sleiman SF, Smirnova NA, Langley BC, Mahishi L, Cooper AJ, Antonyak MA, Cerione RA, Li B, Starkov A, Chaturvedi RK, Beal MF, Coppola G, Geschwind DH, Ryu H, Xia L, Iismaa SE, Pallos J, Pasternack R, Hils M, Fan J, Raymond LA, Marsh JL, Thompson LM, Ratan RR. McConoughey SJ, et al. Among authors: raymond la. EMBO Mol Med. 2010 Sep;2(9):349-70. doi: 10.1002/emmm.201000084. EMBO Mol Med. 2010. PMID: 20665636 Free PMC article.
In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study.
Williams JK, Erwin C, Juhl AR, Mengeling M, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS; I-RESPOND-HD Investigators of the Huntington Study Group. Williams JK, et al. Am J Med Genet B Neuropsychiatr Genet. 2010 Sep;153B(6):1150-9. doi: 10.1002/ajmg.b.31080. Am J Med Genet B Neuropsychiatr Genet. 2010. PMID: 20468062 Free PMC article.
Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study.
Erwin C, Williams JK, Juhl AR, Mengeling M, Mills JA, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS; I-RESPOND-HD Investigators of the Huntington Study Group. Erwin C, et al. Am J Med Genet B Neuropsychiatr Genet. 2010 Jul;153B(5):1081-93. doi: 10.1002/ajmg.b.31079. Am J Med Genet B Neuropsychiatr Genet. 2010. PMID: 20468061 Free PMC article.
NMDA Receptors and Huntington’s Disease.
Fernandes HB, Raymond LA. Fernandes HB, et al. Among authors: raymond la. In: Van Dongen AM, editor. Biology of the NMDA Receptor. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 2. In: Van Dongen AM, editor. Biology of the NMDA Receptor. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 2. PMID: 21204413 Free Books & Documents. Review.
Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function.
Yanai A, Huang K, Kang R, Singaraja RR, Arstikaitis P, Gan L, Orban PC, Mullard A, Cowan CM, Raymond LA, Drisdel RC, Green WN, Ravikumar B, Rubinsztein DC, El-Husseini A, Hayden MR. Yanai A, et al. Among authors: raymond la. Nat Neurosci. 2006 Jun;9(6):824-31. doi: 10.1038/nn1702. Epub 2006 May 14. Nat Neurosci. 2006. PMID: 16699508 Free PMC article.
Wild-type huntingtin protects neurons from excitotoxicity.
Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK, Wellington CL, Raymond LA, Hayden MR. Leavitt BR, et al. Among authors: raymond la. J Neurochem. 2006 Feb;96(4):1121-9. doi: 10.1111/j.1471-4159.2005.03605.x. Epub 2006 Jan 17. J Neurochem. 2006. PMID: 16417581 Free article.
Targeting energy metabolism in Huntington's disease.
Walker FO, Raymond LA. Walker FO, et al. Among authors: raymond la. Lancet. 2004 Jul 24-30;364(9431):312-3. doi: 10.1016/S0140-6736(04)16739-1. Lancet. 2004. PMID: 15276373 No abstract available.
Disruption of the endocytic protein HIP1 results in neurological deficits and decreased AMPA receptor trafficking.
Metzler M, Li B, Gan L, Georgiou J, Gutekunst CA, Wang Y, Torre E, Devon RS, Oh R, Legendre-Guillemin V, Rich M, Alvarez C, Gertsenstein M, McPherson PS, Nagy A, Wang YT, Roder JC, Raymond LA, Hayden MR. Metzler M, et al. Among authors: raymond la. EMBO J. 2003 Jul 1;22(13):3254-66. doi: 10.1093/emboj/cdg334. EMBO J. 2003. PMID: 12839988 Free PMC article.